Medication management during treatment abroad begins before departure. The referring clinician and receiving team need an accurate medication history, a clear reason for any proposed change, and a workable plan for prescribing and monitoring. The patient also needs to confirm that the exact medicines can be taken into the destination and any transit country.
A residential package does not answer these questions by itself. Compare what the service can actually prescribe and monitor, who takes responsibility, and how treatment will continue after the stay. A plan is incomplete if it works only while the patient remains at the clinic.
Build one accurate medication record
NIMH recommends preparing a list of medicines, including nonprescription products, vitamins, and supplements, and discussing symptoms and concerns openly with the health care professional. For an international referral, add the generic name, formulation, current prescribed instructions, purpose, and prescriber’s details.
Include medicines taken occasionally as well as daily prescriptions. Record allergies, previous adverse reactions, treatments that did not help, and the reasons earlier medicines were stopped when known. Do not rely on a translated brand name or a photograph of a box as the entire clinical history.
Ask the receiving team to reconcile the list with the referral records. Reconciliation means resolving discrepancies so that everyone is working from the same account of what the person takes. A recent hospital discharge, several prescribers, or an old repeat prescription can otherwise create uncertainty.
The predeparture assessment guide explains how this information fits into the wider referral. The aim is to help the receiving clinician make informed decisions, including identifying questions that need an answer before travel.
Agree on the purpose of the medication review
A review might confirm an effective regimen, investigate an adverse effect, reassess a diagnosis, or consider a different treatment. These are different tasks. Ask what problem the team intends to address and what information would justify a change.
NIMH explains that people respond differently to mental health medicines and may need individualized treatment choices. A program’s preference for a particular approach should not substitute for assessing the person’s history, current response, other conditions, and preferences.
Ask how the clinician will distinguish a medicine’s possible effects from symptoms, substance use, sleep disruption, or another medical problem. A useful discussion identifies uncertainty and explains how it will be assessed. It does not promise that every longstanding difficulty can be settled during a short stay.
If a service advertises a medication-free approach, establish what that means for someone who already has an effective prescription. Do not interpret the phrase as a clinical reason to stop treatment. The decision belongs in an individualized discussion with the responsible prescriber.
Identify who can prescribe and who remains involved
Ask for the name and role of the clinician responsible for medication decisions at the destination. Clarify which appointments are included, what happens outside routine hours, and who handles a new concern when that clinician is unavailable.
Agree how the receiving team will communicate with the usual prescriber, with the patient’s consent. Decide who will issue prescriptions during the stay and who is expected to resume responsibility afterward. Two clinicians working from different lists can leave the patient unsure which instructions apply.
Do not assume that an existing clinician can prescribe across borders or that a destination prescription will be usable at home. Those arrangements require confirmation with the professionals and relevant authorities. A promised video follow-up does not, by itself, establish a lawful route to obtain medication.
Check whether the required monitoring is available
Medication monitoring should match the medicine and the person’s needs. Ask which examinations or tests are required, where they will occur, who reviews the results, and how abnormal findings are managed. A general statement that medical support is available leaves these responsibilities unclear.
NIMH describes the need for monitoring with particular medicines. For example, lithium treatment requires attention to blood levels and kidney and thyroid function. That is a reason to establish the actual monitoring arrangements, not a reason for a patient to adjust a dose independently.
The CDC Yellow Book discusses additional travel considerations for lithium, including changes related to heat and perspiration and access to laboratory testing. Discuss climate, planned activities, and medical access with the treating clinician before departure.
Ask whether the clinic can obtain previous test results and share new results in a form the home clinician can use. A discharge summary should distinguish completed monitoring from tests that are still needed, with a named person responsible for follow-up.
| Decision | What to establish |
|---|---|
| Continue the current prescription | Confirm supply, prescribing responsibility, monitoring, and how new concerns are reported. |
| Consider a change | Document its purpose, alternatives, follow-up, and the patient’s questions. |
| Travel with a restricted medicine | Confirm the exact medicine, route, quantity, and applicable official permissions. |
| Return home | Arrange an accepted handover, an adequate lawful supply, and access to the next prescription. |
Plan changes around clinical need
Ask how the team will assess benefit and adverse effects after a change. The plan should specify whom to contact, what follow-up is expected, and what happens if the patient returns home before the review is complete. A booking end date is an administrative boundary, not evidence that a medication decision has been fully evaluated.
Keep the rationale for each change in the record. If several changes are being considered, ask how the clinician will interpret the response and explain the sequence. The patient should understand the plan without having to reconstruct it from separate appointment notes.
The FDA warns that abruptly stopping benzodiazepines or reducing them too quickly can cause serious withdrawal. Its opioid safety communication also warns about sudden discontinuation in physically dependent patients. Do not create a taper from a travel timetable or change a prescription without the treating clinician’s guidance.
Our benzodiazepine care guide examines the implications for international treatment. Physical dependence and a substance use disorder require careful assessment; a clinic should explain what it has identified rather than treating the words as interchangeable.
Preserve access to addiction treatment medicines
Medication planning can be central to addiction care. For opioid use disorder, the CDC recommends treatment with appropriate medications and advises against detoxification alone because of the risks associated with returning to opioid use. Psychosocial care can accompany medication treatment.
Before choosing a destination, ask whether the service can continue or provide the clinically recommended treatment and whether there is a realistic route to continue it after discharge. Access at one clinic does not establish access in every country or community.
The opioid treatment continuity guide explores these decisions. If the proposed destination cannot support the treatment plan, discuss alternatives before booking. Do not assume that temporarily replacing ongoing care with withdrawal management serves the same purpose.
Verify entry rules for the exact medicine
The CDC warns that medicines permitted in one country may be restricted or prohibited in another. A prescription from home does not automatically grant permission to carry the medicine across a border. Check the destination and transit countries through their relevant official authorities.
Use the generic name, formulation, amount, route, and travel dates when asking about requirements. Find out whether advance permission, a medical letter, or other documentation is needed. The International Narcotics Control Board’s country information can be a starting point, but CDC advises verifying requirements with the relevant country authorities.
Entry permission and local access are separate questions. Confirm whether the medicine or an appropriate formulation can be prescribed and supplied at the destination if needed. Do not assume that posting a refill or asking another traveler to carry it is permitted.
The travel documents guide helps organize the practical checks. If an essential medicine cannot be taken or obtained lawfully, return to the clinical and destination decision rather than stopping it to make the itinerary work.
Make the journey workable
CDC advises keeping medicines in original labeled containers and carrying them in hand luggage. Ask the prescribing clinician or pharmacist how to handle travel timing, storage needs, and any disruption to the routine. Avoid making your own dose adjustments in response to a time-zone change.
Carry a usable medication summary and the documentation required for the journey. Keep the receiving clinic’s clinical contact details accessible. Establish whom to call if a medicine is lost, a flight changes, or a supply problem threatens continuity.
Confirm what the clinic actually supplies and what the patient must bring. A quoted program fee may not answer questions about outside prescriptions, laboratory work, or specialist consultations. Resolve these items in the written proposal so that practical uncertainty does not delay agreed care.
Complete the handover before departure
Request a final reconciled list that identifies what is continued, changed, or discontinued and why. It should include relevant response, adverse effects, monitoring results, unresolved concerns, and planned reviews. Ask the team to make any differences from the preadmission list clear.
Arrange the next clinical appointment and confirm who will prescribe. Discuss the supply needed to reach that appointment and verify that bringing it home meets applicable rules. A written recommendation is more useful when the receiving professional has accepted the handover and can act on it.
Our aftercare planning guide places medication alongside therapy and other support. The test of an international medication plan is whether the patient can understand it, obtain the agreed treatment, receive appropriate monitoring, and reach a responsible clinician throughout the transition.